ABPI and our Regional Industry GroupsKaren Thomas, Regional Partnership Manager London | ABPI

Focus for the day

• The ABPI • The background to our team• Regional Industry Group – London• Hear from our speakers• Joint working masterclass• What all this means for you

Further reading

http://www.abpi.org.uk/our-work/news/2012/Pages/140512.aspx

Real world data and e-health

ABPI landscape and policy map

Innovation, Health and Wealth

value based pricing

PPRS

Commissioning

Reputation

UK Competitiveness

NHS Partnerships

Discovery Development Approval Fair Price Access Uptake Patients

Supply ChainPartnerships for research

Animal research

EU Influence

Clinical research

Regulatory framework and MHRA

Manufacturing and the environment

Schools, higher education and skills

Intellectual property and patent

Pharmacovigilance

Patient Group Forum

Medicines Optimisation

HTA

IHW - Accelerating adoption and diffusion in the NHS

• Innovation, Health and Wealth report was published on 5th December 2011

• Sir David Nicholson also sent a letter outlining his expectations for NHS action

• ABPI warmly welcomed the report as a significant step forward to support adoption and diffusion of innovative medicines across the NHS

Our partnerships for delivery

• We have an MOU with the NHS Confederation, ABHI and Medilinks to support the implementation of Innovation, Health and Wealth

http://www.nhsconfed.org/priorities/latestnews/Pages/NHS-Confederation-joins-ABPI-ABHI-innovation-project.aspx

• This strategic agreement aims to increase the adoption and diffusion of proven technologies in areas of high clinical need to deliver high quality patient outcome and efficiency gains

• It includes showcasing best practice for joint working, judged by an independent panel – our first launch event was in February

• We work on policy at a national level with a range of organisations, including the DoH, NHS England, NICE, Royal Colleges and others

Both the NHS and pharma have their

challenges….• QIPP Challenge - £20bn in 4 years- and £50bn in future years . “Doing more with less”

• Care scandals – Mid Staffs, Winterbourne and many others - So quality needs to dramatically improve while budgets shrink – and we have just had an NHS reorganisation that’s “so big, you can see it from space”

• As for pharma – are the days of blockbusters over? R&D is getting harder, development is often through acquisition and industry is a global business. Other issues include patent expiry, changing business models, biotech companies – we work in a rapidly shifting environment

Our vision

NHS Partnerships Team established in 2012, led by Carol Blount, our director:

– Kevin Blakemore, National Manager– Regional Managers:

– Di Vegh (South)– Harriet Lewis (North)– Andy Riley (Mids and East)– Karen Thomas (London)

– Mike Ringe, Therapy Group Manager– Terry Harrison, consultant– Industry secondee

currently Farid Bidgoli from AZ

Industry as an integral part of the NHS’s solution to the delivery of better patient outcomes

NHS Partnership team priorities

We are:- Identifying and sharing local NHS issues, organisational and policy changes with member companies- Taking the lead on themes from the Innovation, Health and Wealth and other key priorities, e.g. medicines optimisation- Demonstrating the value of medicines as an opportunity to improve outcomes rather than as a cost pressure to commissioners and providers- Supporting companies in the development of Joint Working projects

We aren’t: - Promoting a particular company/ therapy area or product- Trying to improve your market share- Replicating or ‘competing’ with member company field teams- The only way that the NHS can engage with pharma

1. Wide range of transformational skills, knowledge and experience of Pharma and the new NHS

2. Brokerage to help Pharma and NHS relationships and improve the environment for business to business interaction and shared learning

3. Identifying opportunities and 'partnerships' that involves a mutually beneficial transaction between industry, NHS and other potential partners, that in some cases, an individual company would not be privy to.

4. Understand the barriers to access and what enablers can be used to break these down to bring parties together

5. Experts in the use of the “7 step partnership model” and how it should be used to enable openness & transparency

10

The Partnership team’s USP

Regional Industry Groups• Summer 2012, we wrote to all member company GMs, asking for nominations to sit on our Regional Industry Groups = RIGs

• Individuals had to have at least 5+ years of market access experience at a senior level, and be prepared to take an industry perspective

• The ABPI funds these groups – they are not ‘pay to play’

• Each region was allocated 12 – 15 places and the first meeting took place in the South in November 2012

• We elected a Chair – Stephen Fensome, Almirall – and a deputy Chair – Nick Jones

• The ABPI Regional Manager organises all the meetings and provides secretariat

Joint working in London ?

Quotes on Joint Working

I am appalled when reps come to see me and are ill prepared and don’t do their research . All the

information is in the public domain.

Chief Pharmacist, secondary care

“JW with governance –

fantastic! This is exactly what is

needed.” – Lead Pharmacist, primary care

We want industry to get involved in the projects at the embryonic stage. We

want a long-term sustainable relationship.” - Consultant secondary

care

“I wish this JW criteria existed before. It makes

the NHS feel safer working with industry, especially as the ABPI

is endorsing it.” – Governance Manager

secondary care

“Why doesn’t pharma just provide sponsorship and let

the NHS do the rest?” – Primary

Care lead

“I’m interested in JW, but what does

industry have to offer?” –

Innovation Lead secondary care

“It’s disappointing when pharma

provides financial resources but no other resource.” –

Governance Manager secondary care

“The CCGs are gagging for JW with industry, but it has to

be open & transparent.” – Lead Pharmacist, primary

care

“NHS is wary to work with pharma, so you have to sell the concept of JW.” – Pharmaceutical Advisor primary

care

Thank you & enjoy your meeting